Sarepta Therapeutics shares jump on news of critic’s departure from FDA

Sarepta Therapeutics Inc. shares rose 14.3% in premarket trade Wednesday after reports that a prominent critic of the company’s Duchenne muscular dystrophy drug has left the Food and Drug Administration for another job.

Sarepta SRPT, -7.71% shares have fluctuated significantly over the course of the approval process for the drug, eteplirsen, which would be the only treatment for the genetic disease and has been the focus of significant activism by the patient community.

News of the departure of Dr. Ronald Farkas, who had led a critical FDA review on eteplirsen, was first reported by Benzinga late Tuesday.

>>> Original Source <<<